Physician profile
David E Oakley
NPI 1578523700
$2,382.21
in general payments reported to CMS, 2019-2025
31 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $195 · 2021: $378 · 2022: $315 · 2023: $442 · 2024: $390 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272 · Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.35 |
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $380.77 | 2021-2025 | |
| Astellas Pharma US INC | $292.68 | 2019-2025 | Veozah |
| Novo Nordisk INC | $256.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $207.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.89 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $145.84 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $126.78 | 2019-2024 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $79.57 | 2020-2024 | Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $65.26 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.54 | 2022-2023 | Gattex |
| Merck Sharp & Dohme LLC | $54.45 | 2019-2023 | Vaxneuvance, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $49.37 | 2023-2025 | Gvoke Hypopen |
| Actelion Pharmaceuticals US, INC. | $46.48 | 2021-2025 | Opsumit |
| Exact Sciences Corporation | $45.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $42.43 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.57 | 2019-2022 | |
| Daiichi Sankyo INC. | $37.71 | 2022-2024 | Injectafer |
| Horizon Therapeutics Plc | $37.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.79 | 2024-2025 | Eliquis |
| Amarin Pharma, INC. | $29.75 | 2020 | |
| Allergan, INC. | $22.56 | 2020 | |
| Janssen Pharmaceuticals, INC | $21.72 | 2019 | |
| Corium, LLC | $21.53 | 2024 | Azstarys |
| Biogen, INC. | $20.32 | 2021 | |
| Antares Pharma, INC. | $17.69 | 2024 | Xyosted |
| Dexcom, INC. | $14.60 | 2021 | |
| Baxter Healthcare | $14.27 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $13.37 | 2021 | |
| Therapeuticsmd, INC. | $13.07 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oakley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.